Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of L-DOS47 Plus Vinorelbine/Cisplatin vs Vinorelbine/Cisplatin in Lung Adenocarcinoma
2016-003015-34Phase 2Terminated
- Sponsor
- Helix BioPharma
- Start
- Nov 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of L-DOS47 in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Helix BioPharma. Started Nov 2017; status: terminated.
02
Drugs
L-DOS47
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2016-003015-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003015-34.